Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB for the commercialization of MOB-015 (Terclara) in Europe. The deal spans 19 European markets, enabling a coordinated launch across major EU countries and the United Kingdom under the globally recognized Lamisil brand.
Under the agreement, Karo Healthcare will oversee marketing, distribution, and sales across all covered territories. While financial details were not disclosed, the partnership includes royalty payments and compensation for supplied products.
“Partnering with Karo Healthcare—known for its strong European commercial network—gives us an exceptional opportunity to establish MOB-015/Terclara as a market leader beyond Sweden and Norway,” said Anna Ljung, CEO of Moberg Pharma.
“Combining Moberg’s innovative formulation with the Lamisil brand’s strength positions us uniquely in the antifungal market,” added Christoffer Lorenzen, CEO of Karo Healthcare.
Strategic Market Coverage
The collaboration covers approximately 500 million people across Europe, including the “Big 5” EU markets (France, Germany, Italy, Spain, and the UK) and 11 countries where Terclara is already approved but yet to be launched. Both companies plan to expand marketing authorizations to additional countries as regulatory processes allow.
Although launch timing may vary by market—depending on national health authority approval for the Lamisil brand name—both partners intend to initiate rollout as soon as feasible. Marketing materials will also include the concept “Powered by Terclara” to maintain Moberg Pharma’s product association.
Next-Generation Terbinafine Therapy
Terbinafine, originally introduced by Novartis under the Lamisil brand, remains the gold standard for fungal skin and nail infections such as athlete’s foot and onychomycosis. However, oral terbinafine can cause liver toxicity and drug interactions, limiting long-term use.
MOB-015/Terclara, developed by Moberg Pharma, represents a new topical formulation designed to overcome historical challenges of delivering terbinafine through the nail. In clinical studies, 76% of patients achieved mycological cure, matching oral treatment outcomes for the first time.
About the Companies
Moberg Pharma AB (publ) is a Swedish pharmaceutical company specializing in drug delivery innovations using proven compounds. Its lead product, MOB-015, has market approval in 13 EU countries for the treatment of onychomycosis.
Karo Healthcare AB, backed by global investment firm KKR, is a leading European consumer healthcare company with a pan-European distribution network covering both prescription and OTC products. The company’s capabilities enable rapid market access across key EU pharmacy chains.
The agreement marks a key milestone in Moberg Pharma’s commercial expansion strategy, positioning MOB-015/Terclara as a potential new market leader in antifungal therapy across Europe.
